Iovance Biotherapeutics, INC 10-Q quarterly reports

Iovance Biotherapeutics announced a significant increase in revenue for the quarter ended June 30, 2026, driven by strong sales of Amtagvi and Proleukin, though net losses persist.

Iovance Biotherapeutics Inc. reported a 45% increase in total revenue for the first quarter of 2026, driven by strong Amtagvi and Proleukin sales, while net loss narrowed.

Iovance Biotherapeutics reported strong 37% growth in Amtagvi revenue for Q3 2025, alongside a strategic restructuring, increased net losses, and the withdrawal of its European marketing application for lifileucel.

Iovance Biotherapeutics reported increased net losses in Q2 2025 despite significant Amtagvi revenue growth, alongside a strategic workforce reduction and ongoing legal challenges.

Iovance Biotherapeutics announced its first quarter 2025 financial results, highlighting initial revenue from its newly launched advanced melanoma drug Amtagvi and ongoing Proleukin sales, alongside progress in its clinical pipeline and international regulatory filings.

Iovance Biotherapeutics reports a significant increase in revenue for Q3 2024, primarily driven by the commercial launch of Amtagvi and sales of Proleukin.

Iovance Biotherapeutics reports its first commercial sales of Amtagvi, a novel cancer therapy, contributing to a total revenue of $31.1 million for the second quarter of 2024.

Iovance Biotherapeutics reports a net loss of $113 million for the first quarter of 2024, while initiating the commercial launch of Amtagvi and generating revenue from Proleukin sales.